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Oral trimethoprim-sulfamethoxazole in the treatment of 
cerebral toxoplasmosis in AIDS patients - a prospective 
study 
P Francis, V B Patel, P L A Bill, A I Bhigjee 
Toxopla$ma encephalitis is the commonest cause of 
intracranial mass lesions in AIDS patients, Effective therapy 
includes pyrimethamine plus sulfadiazine, dindamycin 
with pyrimethamine, and co-trimoxazole. This study 
Toxoplasmosis is the most frequent cause of focal cerebral 
lesions in patients with AIDS.' Current therapy for acute 
cerebral toxoplasmosis is a combination of pyrimethamine plus 
sulfadiazine.' Alternative agents include clindamycin, 
clarithromycin and azithromycin.3•4 In addition to the 
significant adverse effect profile of the pryimethamine 
combination, necessitating folinic acid replacement, none of 
these agents is available in intravenous form in most public 
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examines the efficacy of oral co-trimoxazole in 20 A.lDS 
patients with toxoplasmosis and seeks to confirm the 
experience of Torre et al. 
S Afr Med J 2004; 94: 51-53. 
service hospitals within the province of KwaZulu-Natal. The 
combination of trimethoprim-sulfamethoxazole (co- liJI 
trimoxazole) has been shown to possess antitoxoplasmic 
activity in vitro3 and in vivo.'·' The latter study,' a retrospective 
appraisal of intravenous therapy, showed a favourable 
outcome in 87% of treated patients. The aim of the present 
study was to prospectively evaluate the efficacy of oral co-
trimoxazole in acute cerebral toxoplasmosis. 
ORIGINAL ARTICLES 
Methods 
}ltV-positive patients referred to the neurology unit with 
radiological lesions suggestive of toxoplasmosis (multiple 
lesions with rim enhancement, basal ganglia location, extensive 
surrounding oedema) were entered into the study. Computed 
tomography (CT) scans were performed on admission, before 
commencing therapy. Repeat scans were done 2 - 4 weeks later, 
except when neurological deterioration necessitated an earlier 
scan. Patients qualifying for entry into the study were treated 
with trimethoprim-sulfamethoxazole (co-trimoxazole 80 mg 
and 400 mg respectively). An induction dose of 2 tablets 4 
times daily for 1 month was followed by 2 tablets 12-hourly for 
life in the absence of antiretroviral therapy and a CD4 count 
below 200 cells/}1!. This dose is comparable with the 
international literature which cites doses of 10 and 50 
mg/kg/ day of trimcthoprim-sulfamethoxazole respectively. 
Clinical improvement was taken to indicate diagnostic 
accuracy. Non-responders were referred to the neurosurgeons 
for a stereotactic biopsy. Patients who refused consent for a 
biopsy were started on antituberculosis treatment with or 
without dexamethasone. All non-responders were excluded 
from further statistical analysis. Treatment efficacy was 
ascertained by clinical and/ or radiological improvement. 
Serological tests included HlV enzyme-linked immunosorbent 
assay (ELJSA) and Toxoplasma gondii antibodies, while CD4 cell 
counts were available in 7 patients. In the latter phase of the 
study, magnetic resonance imaging (MRI) scans were also 
done. 
Results 
Twenty patients completed the study. There was an equal 
number of male and female patients. The mean age at 
presentation was 32 years. Hemiparesis was the commonest 
presenting symptom (77%), followed by mental status changes 
(62%) and seizures (23%). All patients were H!V-positive. CD4 
counts were available for 7 patients. These ranged from 1 
cell/rl to 78 cells/rl. T. gondii antibodies were positive in 8 of 
20 patients. All patients showed complete or partial clinical and 
radiological improvement (Figs ]a, b, 2a, b). The improvement 
was sustained on the selected maintenance regimen of 2 tablets 
12-hourly. However, not all patients continue to attend for 
follow-up so the long-term outcome remains speculative. No 
significant cutaneous side-effects were noted in our study 
group, although a few developed minor gastrointestinal upset. 
Discussion 
This study establishes the efficacy of oral co-trimoxazole as 
therapy for acute cerebral toxoplasmosis in the doses 
described. This has significant utility in the public sector. It is 
recommended that oral co-trimoxazo\e be implemented as 
first-line therapy in cases of suspected cerebral toxoplasmosis. 
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Fig. la. Pre-treatment contrast-enhanced CT scan showing a 
hypodense lesion in the left basal ganglia with rim enhancement and 
surrounding oedema, causing effacement of the third ventricle and 
midline shift. 
Fig. lb. Post-treatment contrast-enhanced CT scan of the same 
patient showing resolution of the oedema, decrease in contrast uptake 
and residual hypodensity. 
ORIGINAL ARTICLES 
Fig. 2a. Pre-treatment Tl MRI scan showing hypodense lesion in the 
left basal ganglia with mass effect and midline shift. 
A limitation of this study is that many of the non-responders 
declined a biopsy and were treated empirically. Hence the 
aetiology of these lesions remains hypothetical. It is therefore 
unclear whether all non-responders have an alternative 
diagnosis or whether there is a sub-group of cerebral 
toxoplasmosis that is unresponsive to co-trimoxazole therapy. 
Conclusion 
Oral co-trimoxazole is effective for acute toxoplasma 
encephalitis in doses of 2 tablets 4 times daily for 1 month 
followed by 2 tablets twice daily as secondary prophylaxis for 
life. Lifetime prophylactic therapy for toxoplasmosis would 
only apply if patients are not receiving antiretroviral therapy 
with the CD4 count being under 200 cells/].11. 
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Fig. 2b. T2 MRl picture of the same area showing central 
hypodensity and surrounding high signal. 
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